Keywords: par, 3rd, qtr, net, falls, strativa, costs
Par's 3rd qtr net falls 70% on Strativa costs
Article | 14 January 2008
Third quarter 2007 net income at New Jersey, USA-based generic drugmaker Par Pharmaceutical fell 70.5% to $1.3 million, or $0.04 per share, as a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
